MIM
ALNY icon

Macroview Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Macroview Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-51
Closed -$7.62K – 589
2024
Q1 		$7.62K Buy
51
+9
+21% +$1.5K 0.01% 329
2023
Q4 		$8.04K Buy
42
+36
+600% +$6.13K 0.01% 282
2023
Q3 		$1.06K Buy
+6
New +$1.15K ﹤0.01% 652
2019
Q4 		– Sell
-45
Closed -$4K – 298
2019
Q3 		$4K Buy
+45
New +$3.56K 0.01% 174

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Macroview Investment Management's ALNY Position: Q2 2024 in Review

Macroview Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 51 shares — an estimated $7.62K sold.

Macroview Investment Management first reported a position in ALNY in Q3 2019 and held it in 4 quarters. The position peaked at $8.04K in Q4 2023. 523 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Macroview Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Macroview Investment Management sold 51 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $7.62K.
  • Macroview Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Macroview Investment Management's Alnylam Pharmaceuticals position peaked at $8.04K in Q4 2023.
  • 523 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Macroview Investment Management's 13F filing for Q2 2024, filed 23 Jul 2024.